Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 4Recurrence 1Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Gemcitabine 30Mitomycin 25BCG Vaccine 13Docetaxel 10Epirubicin 6erdafitinib 5durvalumab 5dodecyl maltoside 5Radiotherapy 5Cystoscopy 5apaziquone 4ALT-803 4tislelizumab 35-aminolevulinic acid hexyl ester 3viscum album peptide 2pembrolizumab 2disitamab vedotin 2avelumab 2VB4-845 2Therapeutics 2Imiquimod 2Hyaluronic Acid 2Administration, Intravesical 21-phenyl-3,3-dimethyltriazene 2vocimagene amiretrorepvec 1valrubicin 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × BCG Connaught × Clear all
NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

A.O.U. Città della Salute e della Scienza

Phase 2 Completed
120 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡